Preventive carnosine supplementation attenuates painful diabetic neuropathy via restoring mitochondrial function and suppressing inflammasome activation

Figure 5 The screening of optimal carnosine concentration in PC12 cells. ^bP < 0.01, ^cP < 0.001 vs the control group; ^dP < 0.05, ^eP < 0.01, ^fP < 0.001 vs the high-glucose (HG) group. One-way analysis of variance with Tukey’s multiple comparisons test for Figure 5A-C, E and F. For Figure 5A-C, n = 3; for Figure 5D-F, n = 4. A: Cell counting kit-8 (CCK-8) assay of viability in PC12 cells treated with HG and mannitol; B: CCK-8 assay of viability in PC12 cells treated with various concentrations of carnosine in a standard culture medium; C: CCK-8 assay of viability in PC12 cells treated with different concentrations of carnosine in a HG culture medium; D-F: Western blotting indicating changes in the expression levels of mitochondrial fission protein dynamin-related protein 1 and NOD-like receptor pyrin domain-containing protein 3 inflammasome in PC12 cells treated with various concentrations of carnosine in a HG culture medium. NLRP3: NOD-like receptor pyrin domain-containing protein 3; Drp1: Dynamin-related protein 1; HG: High-glucose.